Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment

Polish Journal of Pharmacology

Volumn 49, Issue 6, 1997, Pages 439-452

  Daniel, Władysława A ^a   Syrek, Maciej ^a   Mach, Anna ^a   Wójcikowski, Jacek ^a   Boksa, Jan ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Brain; Mesoridazine; N desmethylthioridazine; Pharmacokinetics; Plasma; Ring sulfoxide; Sulforidazine; Thioridazine

Indexed keywords

DRUG METABOLITE; MESORIDAZINE; SULFORIDAZINE; THIORIDAZINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG REEXPOSURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACOKINETICS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MESORIDAZINE; PHENOTHIAZINES; RATS; RATS, WISTAR; THIORIDAZINE; TISSUE DISTRIBUTION;

EID: 0031439133     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Axelsson R.: On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone in chronic psychotic patients. Cum Ther. Res. Clin. Exp., 1977, 21, 587-605.
2. Baumann P., Meyer J. W., Amey M., Baettig D.,Bryois C., Jonzier-Perey M., Koeb L., Monney C., Woggon B.: Dextrometorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit., 1992, 14, 1-8.
3. Blake B. L., Rose R. L., Mailman R. B., Levi P. E., Hodgson E.: Metabolism of thioridazine by microsomal monooxygenases: relative roles of P-450 and flavin-containing monooxygenase. Xenobiotica, 1995, 25, 377-393.
4. Bowers M. B., Rozitis A.: Brain homovanillic acid: regional changes over time with antipsychotic drugs. Eur. J. Pharmacol., 1976, 39, 109-115.
5. Bylund D. B.: Interactions of neuroleptic metabolites with dopaminergic, alpha-adrenergic and muscarinic cholinergic receptors. J. Pharmacol. Exp. Ther., 1981, 217, 81-86.
6. Cohen B. M., Lipiński J. F., Waternaux C.: A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology, 1989, 97, 481-488.
7. Costal B., Naylor R. J.: Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia-Berlin, 1975, 43, 69-74.
8. Costall B., Naylor R. J.: A comparison of the ability of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonize the hyperactivity induced by DA applied intracerebrally to areas of the extra-pyramidal and mesolimbic systems. Eur. J. Pharmacol., 1976, 40, 9-19.
9. Daniel W.: Metabolism of psychotropic drugs: Pharmacological and clinical relevance. Pol. J. Pharmacol., 1995, 47, 367-379.
10. Daniel W., Syrek M., Janczar L., Boksa J.: The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats - a comparison with the pharmacokinetics of imipramine. Pol. J. Pharmacol., 1995, 47, 127-136.
11. Daniel W. A., Wójcikowski J.: Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol., 1997, 80, 62-68.
12. Dinovo E. C., Bost R. O., Sunshine I., Gottshalk L. A.: Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. Clin. Chem., 1978, 24, 1828-1830.
13. Fauster R., Honegger U. E., Wiesmann U. N.: Inhibition of phospholipid degradation and changes of the phospholipid pattern by desipramine in cultured human fibroblasts. Biochem. Pharmacol., 1983, 32, 1737-1744.
14. Gottschalk L. A., Dinovo E., Biener R., Nandi B. R.: Plasma concentrations of thioridazine metabolites and ECG abnormalities. J. Pharm. Sci., 1978, 67, 155-157.
15. Hyttel J., Larsen J. J., Christensen A. V., Amt J.: Receptor binding profiles of neuroleptics. In: Dyskinesia Research and Treatment. Eds. Casey D. E., Chase T. N., Christensen A. V., Gerlach J., Springer, Berlin, Heidelberg, 1985, 9-18.
16. Javaid J. I.: Clinical pharmacokinetics of antipsychotics. J. Clin. Pharmacol., 1994, 34, 286-295.
17. Lai H., Carino M. A., Sperry R., Horita A.: Effects of thioridazine on apomorphine-elicited stereotyped behavior and motor activity. Pharmacol. Biochem. Behav., 1980, 13, 397-401.
18. Lin G., Hawes E. M., McKay G., Korchinski E. D., Midha K. K.: Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica, 1993, 23, 1095-1074.
19. Lüllmann H., Wehling M.: The binding of drugs to different polar lipids in vitro. Biochem. Pharmacol., 1979, 28, 3409-3415.
20. MacIntyre A., Cutler D. J.: The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug Dispos. 1988, 9, 513-526.
21. Maj J., Baran L., Bigajska K., Rogóz Z., Skuza G.: The influence of neuroleptics on the behavioural effect of 5-hydroksytryptophan. Pol. J. Pharmacol. Pharm., 1978, 30, 431-440.
22. Meyer J. W., Woggon B., Baumann R, Meyer U. A.: Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin. Pharmacol., 1990, 39, 613-614.
23. Mohammad T., Midha K. K., Haves E. M.: Synthesis of deuterium labelled analogues of S-oxidative metabolites of thioridazine. J. Label. Compound Radiopharm., 1989, 27, 181-188.
24. Montzka T. A., Motiskella J. D., Partyka R. A.: 2,2,2-Trichloroethyl-chloroformate: a general reagent for demethylation of tertiary methylamine. Tetrahedron Lett., 1974, 14, 1325-1327.
25. Moor M., Honegger U. E., Wiesmann U. N.: Organspecific, qualitative changes in the phospholipid composition of rats after chronic administration of the antidepressant drug desipramine. Biochem. Pharmacol., 1988, 37, 2035-2039.
26. Niedzwiecki D. M., Mailman R. B., Cubeddu L. X.: Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. J. Pharmacol. Exp. Ther., 1984, 228, 636-639.
27. Nyberg G., Axelsson R., Martensson E.: Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur. J. Clin. Pharmacol., 1978, 14, 341-350.
28. Nyberg G., Axelsson R., Martensson E.: Cerebrospinal fluid concentrations of thioridazine and its main metabolites in psychiatric patients. Eur. J. Clin. Pharmacol., 1981, 19, 139-148.
29. Papadopoulos A. S., Crammer J. L., Cowan D. A.: Phenolic metabolites of thioridazine in man. Xenobiotica, 1995, 15, 309-316.
30. Richelson E., Nelson A.: Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol., 1984, 103, 197-204.
31. Svendsen C. N., Bird E. D.: HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain. Psychopharmacology, 1986, 90, 316-321.
32. Tsuneizumi T., Babb S. M., Cohen B. M.: Drug distribution betweeen blood and brain as a determinant of antipsychotic drug effects. Biol. Psychiat., 1992, 32, 817-824.
33. von Bahr C., Movin G., Nordin C., Liden A., Hammarlund-Udenaes M., Hedberg A., Ring H., Sjögvist F.: Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther., 1991, 49, 234-240.
34. von Bahr C., Spina E., Birgersson C., Ericsson O., Goransson M., Henthorn T.: Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol., 1985, 34, 2501-2505.
35. Wagner J. G.: Relevant pharmacokinetics. In: Biopharmaceutics and Relevant Pharmacokinetics. Eds. Wagner J. G., Pernarowski M., Drug Intelligence Publications, Hamilton, Illinois, 1971, 237-357.
36. Walters J. R., Roth R. H.: Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmied. Arch. Pharmacol., 1976, 296, 5-14.
37. Widerlöv E., Häggström J. E., Kilts C. D., Andersson U., Breese G. R., Maolman R. B.: Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiat. Scand., 1982, 66, 294-305.
38. Wiesel F. A., Sedvall G.: Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercule of the rat. Eur. J. Pharmacol., 1975, 30, 364-367.
39. Zehnder K., Kalberer F., Kreis W., Rutschmann J.: The metabolism of thioridazine (Mellaril) and one of its pyrrolidine analogues in the rat. Biochem. Pharmacol., 1962, 11, 535-550.